These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 23647720

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
    Yang W, Ma J, Hong T, Liu M, Miao H, Peng Y, Wang C, Xu X, Yang T, Nielsen AM, Pan L, Liu W, Zhao W.
    Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.
    Farshchi A, Aghili R, Oskuee M, Rashed M, Noshad S, Kebriaeezadeh A, Kia M, Esteghamati A.
    BMC Endocr Disord; 2016 Jun 09; 16(1):35. PubMed ID: 27278922
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [The predictive factors of good glycaemic control in Chinese patients receiving biphasic insulin as part 30: a subgroup analyses from the A1 chieve study].
    Hong J, Lei M, Chang B, Gao Z, Wang Z, Zhang X, Zhuang X, Chen B, Xu M, Yang W.
    Zhonghua Nei Ke Za Zhi; 2015 Aug 09; 54(8):705-10. PubMed ID: 26674627
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G.
    Clin Ther; 2005 Aug 09; 27 Suppl B():S57-74. PubMed ID: 16519038
    [Abstract] [Full Text] [Related]

  • 34. Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study.
    Sharma SK, Joshi SR, Kumar A, Unnikrishnan AG, Hoskote SS, Moharana AK, Chakkarwar PN, Vaz JA, PRESENT Study Group.
    J Assoc Physicians India; 2008 Nov 09; 56():859-63. PubMed ID: 19263683
    [Abstract] [Full Text] [Related]

  • 35. Clinical experience with BIAsp 30: Results from the Bangladesh cohort of the global A1chieve study.
    Latif ZA, Pathan MF, Mannan MA, Siddiqui MN, Ashrafuzzaman SM, Rahman MM, Sobhan MJ.
    Bangladesh Med Res Counc Bull; 2013 Dec 09; 39(3):93-8. PubMed ID: 26118154
    [Abstract] [Full Text] [Related]

  • 36. Multicenter, open-label, non-randomized, non-interventional observational study of safety of treatment initiation with a biphasic insulin aspart.
    Wolnik B, Hak L.
    Expert Opin Drug Saf; 2013 Mar 09; 12(2):137-44. PubMed ID: 23289795
    [Abstract] [Full Text] [Related]

  • 37. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.
    Gumprecht J, Benroubi M, Borzi V, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Int J Clin Pract; 2009 Jun 09; 63(6):966-72. PubMed ID: 19504715
    [Abstract] [Full Text] [Related]

  • 38. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
    Niskanen L, Leiter LA, Franek E, Weng J, Damci T, Muñoz-Torres M, Donnet JP, Endahl L, Skjøth TV, Vaag A.
    Eur J Endocrinol; 2012 Aug 09; 167(2):287-94. PubMed ID: 22660026
    [Abstract] [Full Text] [Related]

  • 39. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J, Cohen N, Evans M, Hockey A, Speight J, Whately-Smith C.
    Diabetes Obes Metab; 2015 Dec 09; 17(12):1133-41. PubMed ID: 26085028
    [Abstract] [Full Text] [Related]

  • 40. Real-world study of ethnic differences in glycaemic control and clinical characteristics among insulin-naïve people with type 2 diabetes initiating biphasic insulin aspart 30/70: A retrospective, observational cohort study in England.
    Davies MJ, Alibegovic AC, Jensen AB, Munikrishnappa R, Nordsborg RB, Braae UC.
    Diabetes Obes Metab; 2023 Sep 09; 25(9):2756-2764. PubMed ID: 37334526
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.